{"id":12003,"date":"2021-04-06T16:48:02","date_gmt":"2021-04-06T11:18:02","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=12003"},"modified":"2021-07-24T12:58:20","modified_gmt":"2021-07-24T07:28:20","slug":"recent-pharma-happenings-for-cidara-jj-supernus-rain","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cidara-jj-supernus-rain","title":{"rendered":"Cidara Therapeutics and J&#038;J\u2019s USD 780M Deal; FDA\u2019s Approval to Supernus\u2019s ADHD drug; Rain Therapeutics USD 100M IPO; NMPA Approval to Antengene\u2019s ATG-019 IND Application"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69e6da6d672cd\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69e6da6d672cd\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cidara-jj-supernus-rain\/#Cidara_Therapeutics_Inks_USD_780M_Deal_with_J_J\" >Cidara Therapeutics Inks USD 780M Deal with J&amp;J<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cidara-jj-supernus-rain\/#FDAs_Go-ahead_to_Supernuss_novel_ADHD_drug_Qelbree\" >FDA\u2019s Go-ahead to Supernus\u2019s novel ADHD drug, Qelbree&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cidara-jj-supernus-rain\/#Rain_Therapeutics_Newest_Adventure_Plans_USD_100_Million_IPO\" >Rain Therapeutics\u2019 Newest Adventure, Plans USD 100 Million IPO<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cidara-jj-supernus-rain\/#Antengene_Announces_NMPA_Approval_of_IND_Application_for_ATG-019\" >Antengene Announces NMPA Approval of IND Application for ATG-019<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-cidara-therapeutics-inks-usd-780m-deal-with-j-j\"><span class=\"ez-toc-section\" id=\"Cidara_Therapeutics_Inks_USD_780M_Deal_with_J_J\"><\/span><strong>Cidara Therapeutics Inks USD 780M Deal with J&amp;J<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The share price of Cidara observed a sudden jump after the news of the collaboration of the company with J&amp;J came. Cidara Therapeutics has announced a deal with Johnson &amp; Johnson to develop and commercialize Cidara\u2019s candidate <strong>CD388 <\/strong>to prevent and treat seasonal and pandemic <a href=\"https:\/\/www.delveinsight.com\/report-store\/influenza-a-infections-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">influenza<\/a>.&nbsp;<\/p>\n\n\n\n<p>Under the terms and conditions of the agreement, Janssen (J&amp;J\u2019s company) will pay Cidara an aggregate&nbsp; amount of USD 753 million (upfront USD 27 million) as budget for development of the candidate, milestone and regulatory payments along with royalties on sales. While Cidara will skim the candidate through the phase II clinical development, Janssen will take hold of the candidate in the late-stage development as well as manufacturing and global commercialization.&nbsp;<\/p>\n\n\n\n<p>One of&nbsp; the other Cidara\u2019s Cloudbreak antiviral conjugates (AVCs), CD388 is under rigorous trials for serious fungal and viral infections, and also possesses the powers to prevent the advent of flu. The advantage the therapy holds over available marketed vaccines for the same-says the company is that its tolerability, safety and efficacy to be used in populations of all age groups. Further, the therapy may also have therapeutic prowess same as that of widely-used Tamiflu.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-s-go-ahead-to-supernus-s-novel-adhd-drug-qelbree\"><span class=\"ez-toc-section\" id=\"FDAs_Go-ahead_to_Supernuss_novel_ADHD_drug_Qelbree\"><\/span><strong>FDA\u2019s Go-ahead to Supernus\u2019s novel ADHD drug, Qelbree&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Supernus became the spearhead in the industry after the USFDA gave green signal to its novel non-stimulant therapy, <strong>Qelbree<\/strong>, for <a href=\"https:\/\/www.delveinsight.com\/report-store\/attention-deficit-hyperactivity-disorder-adhd-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\"><em>attention-deficit hyperactivity disorder<\/em><\/a> (ADHD) in pediatric patients falling in the age group of 6 to 17 years.<\/p>\n\n\n\n<p>Earlier known as SPN-812, Qelbree, is a serotonin norepinephrine modulating agent, and the first non-stimulant treatment for ADHD to get approval. The active ingredient in the therapy (<em>viloxazine hydrochloride<\/em>) has an extensive safety record in Europe, where it was previously marketed for many years as an antidepressant, the company said.<\/p>\n\n\n\n<p>As per the data from the trials, the therapy was investigated in more than 1,000 pediatric patients in four phase III clinical trials and showed efficacy on both hyperactivity\/impulsivity and inattention subscales with statistical significance in patients. The news was a huge relief after the regulatory agency issued a Complete Response Letter in sight of concerns related to the relocation of the company\u2019s in-house laboratory.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-rain-therapeutics-newest-adventure-plans-usd-100-million-ipo\"><span class=\"ez-toc-section\" id=\"Rain_Therapeutics_Newest_Adventure_Plans_USD_100_Million_IPO\"><\/span><strong>Rain Therapeutics\u2019 Newest Adventure, Plans USD 100 Million IPO<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>California-based oncology company, Rain Therapeutics, recently filed for a USD 100 million IPO to boost the clinical development and manufacturing of its lead MDM2 inhibitor to the late-stage of testing.<\/p>\n\n\n\n<p>The new program of the company, <strong>RAIN-32<\/strong>, has successfully completed phase I clinical stage in solid tumors and lymphomas and plans to advance it to the phase III stage of clinical testing in liposarcoma, and two more Phase II trials in solid tumors and intimal <a href=\"https:\/\/www.delveinsight.com\/report-store\/clear-cell-sarcoma-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">sarcoma<\/a>, respectively.<\/p>\n\n\n\n<p>Looks like Rain Therapeutics is collecting cash to strengthen and expand its pipeline. Not less than a year ago, the company pulled in a research program from Drexel University, a Phase II-ready drug from Daiichi followed with another hefty funding of USD 63 million.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-antengene-announces-nmpa-approval-of-ind-application-for-atg-019\"><span class=\"ez-toc-section\" id=\"Antengene_Announces_NMPA_Approval_of_IND_Application_for_ATG-019\"><\/span><strong>Antengene Announces NMPA Approval of IND Application for ATG-019<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Antengene Corporation announced the approval of the Investigational New Drug (IND) application for a Phase I clinical trial to test the safety and efficacy of <strong>ATG-019<\/strong> (monotherapy or combined with niacin ER) in patients with advanced solid tumors or <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-hodgkins-lymphoma-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">non-Hodgkin&#8217;s lymphoma <\/a>(NHL) in China from the National Medical Products Administration (NMPA).&nbsp;<\/p>\n\n\n\n<p>ATG-019 is an orally bioavailable dual PAK4\/NAMPT inhibitor that facilitates antitumor activity, inhibits DNA repair, hampers cell cycle progression, and ultimately leads to cell apoptosis. The drug can produce anti-tumor activities in both hematological and solid tumor cells that are dependent on PAK4 and NAMPT pathways; and this makes the drug an interesting and promising therapy.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Antengene is conducting a Phase I clinical trial (TEACH) of ATG-019 in advanced solid tumors and NHL in Taiwan and plans to further proceed with trials testing its combination potential with other agents.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cidara Therapeutics Inks USD 780M Deal with J&amp;J The share price of Cidara observed a sudden jump after the news of the collaboration of the company with J&amp;J came. Cidara Therapeutics has announced a deal with Johnson &amp; Johnson to develop and commercialize Cidara\u2019s candidate CD388 to prevent and treat seasonal and pandemic influenza.&nbsp; Under [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":12006,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[16250,18787,667,862],"industry":[17225],"therapeutic_areas":[17233,17228,17433,17234],"class_list":["post-12003","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-adhd","tag-johnson-jhonsons","tag-lymphoma","tag-non-hodgkins-lymphoma","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology","therapeutic_areas-pediatrics","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Cidara\/J&amp;J\u2019s Deal; Supernus\u2019s ADHD drug Qelbree; Rain&#039;s USD 100M IPO<\/title>\n<meta name=\"description\" content=\"Cidara Therapeutics and J&amp;J\u2019s USD 780M Deal; FDA\u2019s Approval to Supernus\u2019s ADHD drug; Rain Therapeutics USD 100M IPO; Antengene\u2019s ATG-019\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cidara-jj-supernus-rain\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cidara\/J&amp;J\u2019s Deal; Supernus\u2019s ADHD drug Qelbree; Rain&#039;s USD 100M IPO\" \/>\n<meta property=\"og:description\" content=\"Cidara Therapeutics and J&amp;J\u2019s USD 780M Deal; FDA\u2019s Approval to Supernus\u2019s ADHD drug; Rain Therapeutics USD 100M IPO; Antengene\u2019s ATG-019\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cidara-jj-supernus-rain\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-06T11:18:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/06164708\/recent-pharma-biotech-news-updates-for-cidara-jj-supernus-rain.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"773\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cidara\/J&J\u2019s Deal; Supernus\u2019s ADHD drug Qelbree; Rain's USD 100M IPO","description":"Cidara Therapeutics and J&J\u2019s USD 780M Deal; FDA\u2019s Approval to Supernus\u2019s ADHD drug; Rain Therapeutics USD 100M IPO; Antengene\u2019s ATG-019","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cidara-jj-supernus-rain","og_locale":"en_US","og_type":"article","og_title":"Cidara\/J&J\u2019s Deal; Supernus\u2019s ADHD drug Qelbree; Rain's USD 100M IPO","og_description":"Cidara Therapeutics and J&J\u2019s USD 780M Deal; FDA\u2019s Approval to Supernus\u2019s ADHD drug; Rain Therapeutics USD 100M IPO; Antengene\u2019s ATG-019","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cidara-jj-supernus-rain","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-04-06T11:18:02+00:00","article_modified_time":"2021-07-24T07:28:20+00:00","og_image":[{"width":773,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/06164708\/recent-pharma-biotech-news-updates-for-cidara-jj-supernus-rain.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cidara-jj-supernus-rain","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cidara-jj-supernus-rain","name":"Cidara\/J&J\u2019s Deal; Supernus\u2019s ADHD drug Qelbree; Rain's USD 100M IPO","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cidara-jj-supernus-rain#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cidara-jj-supernus-rain#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/06164708\/recent-pharma-biotech-news-updates-for-cidara-jj-supernus-rain.jpg","datePublished":"2021-04-06T11:18:02+00:00","dateModified":"2021-07-24T07:28:20+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Cidara Therapeutics and J&J\u2019s USD 780M Deal; FDA\u2019s Approval to Supernus\u2019s ADHD drug; Rain Therapeutics USD 100M IPO; Antengene\u2019s ATG-019","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cidara-jj-supernus-rain"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cidara-jj-supernus-rain#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/06164708\/recent-pharma-biotech-news-updates-for-cidara-jj-supernus-rain.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/06164708\/recent-pharma-biotech-news-updates-for-cidara-jj-supernus-rain.jpg","width":773,"height":482,"caption":"recent-pharma-biotech-news-updates-for-cidara-jj-supernus-rain"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/06164708\/recent-pharma-biotech-news-updates-for-cidara-jj-supernus-rain-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ADHD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Johnson &amp; Jhonson\u2019s<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-Hodgkin&#039;s Lymphoma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">ADHD<\/span>","<span class=\"advgb-post-tax-term\">Johnson &amp; Jhonson\u2019s<\/span>","<span class=\"advgb-post-tax-term\">lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Non-Hodgkin&#039;s Lymphoma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Apr 6, 2021","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Apr 6, 2021 4:48 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"recent-pharma-biotech-news-updates-for-cidara-jj-supernus-rain","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12003","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=12003"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12003\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/12006"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=12003"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=12003"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=12003"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=12003"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=12003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}